This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thom Rowland Joins Arbor Pharmaceuticals As Vice President Of Commercial Operations

ATLANTA, Nov. 6, 2012 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today that Thom Rowland has joined the company as VP of Commercial Operations. Mr. Rowland is an industry veteran who started his career starting as a sales representative for UCB Pharmaceuticals.  He later held various marketing positions with UCB prior to taking the position of head of marketing for Scandipharm. He played a lead role in turning the Scandipharm business around prior to its sale to Axcan Pharmaceuticals. Thom then served as a VP of Sales and Marketing for several business units at Solvay Pharmaceuticals where he was again instrumental in turning around an underperforming area. Thom was one of the founders of Ventrus Biosciences which completed a successful IPO in 2010.  

Ed Schutter, President and CEO of Arbor, commented, "We are pleased that Thom has joined Arbor at this crucial time in our development as an organization. As our business grows and we become more complex, we felt it was essential that we have someone of Thom's level of experience on board. I'm confident Thom will optimize our current business as well as our future product launches."

Mr. Rowland added, "Arbor has achieved tremendous growth over its short history and is well positioned for future growth.  I am pleased to be joining this highly productive organization at this exciting time and look forward to leading the commercial team to continued success."

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, pediatric and hospital markets. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets multiple NDA and ANDA approved products with several more in development.

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs